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Abstract
Background: The availability of simple and accurate 
assays of plasma active renin (DRC) and aldosterone con­
centration (PAC) can improve the detection of secondary 
forms of arterial hypertension. Thus, we investigated the 
performance of an automated chemiluminescent assay for 
DRC and PAC in referred hypertensive patients.
Methods: We prospectively recruited 260 consecu­
tive hypertensive patients referred to an ESH Center for 
 Hypertension. After exclusion of six protocol violations, 
254 patients were analyzed: 67.3% had primary hyperten­
sion, 17.3% an aldosterone producing adenoma (APA), 
11.4% idiopathic hyperaldosteronism (IHA), 2.4% reno­
vascular hypertension (RVH), 0.8% familial hyperaldo­
steronism type 1 (FH­1), 0.4% apparent mineralocorticoid 
excess (AME), 0.4% a renin­producing tumor, and 3.9% 
were adrenalectomized APA patients. Bland­Altman plots 
and Deming regression were used to analyze results. The 
diagnostic accuracy (area under the curve, AUC of the 
ROC) of the DRC­based aldosterone­renin ratio (ARRCL) 
was compared with that of the PRA­based ARR (ARRRIA) 
using as reference the conclusive diagnosis of APA.
Results: At Bland­Altman plot, the DRC and PAC assay 
showed no bias as compared to the PRA and PAC assay. 
A tight relation was found between the DRC and the 
PRA values (concordance correlation coefficient = 0.92, 
p < 0.0001) and the PAC values measured with radioimmu­
noassay and chemiluminescence (concordance correlation 
coefficient = 0.93, p < 0.001). For APA identification the AUC 
of the ARRCL was higher than that of the ARRRIA [0.974 (95% 
CI 0.940–0.991) vs. 0.894 (95% CI 0.841–0.933), p = 0.02].
Conclusions: This rapid automated chemiluminescent 
DRC/PAC assay performed better than validated PRA/
PAC radioimmunoassays for the identification of APA in 
referred hypertensive patients.
Keywords: aldosterone; aldosteronism; renin assay; sec­
ondary hypertension.
Introduction
Potentially curable secondary forms of arterial hyperten­
sion (HT) are markedly under diagnosed even though the 
ESH/ESC guidelines recommend that they be looked for 
in hypertensive patients fulfilling certain features [1]. This 
strategy recently led to detect these forms in about half of 
the patients with resistant HT referred to tertiary centers 
[2], which is 50­fold more than the current detection rate 
in common general clinical practice.
The under detection of secondary forms of HT not only 
results into lifelong costly medical treatment, but more 
importantly, into an excess damage of the target organs 
of HT, which translates into an excess rate of otherwise 
preventable cardiovascular events [3, 4]. Hence, this is a 
clinical disaster that needs urgent measures.
An accurate assessment of the renin­ angiotensin­
aldosterone system (RAAS) is key to a successful 
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identification of secondary forms of HT [5]. Hence, the 
development of accurate assays for measuring renin and 
aldosterone that are simple, fast, and easy to implement 
in real life practice can represent a major leap forward 
to accelerate and facilitate diagnosis and decrease the 
costs of undiagnosed HT. To this aim, nonradioactive 
methods for the simultaneous measurement of active 
renin and aldosterone are much desirable, as they are 
less labor­and time­consuming and thus ultimately 
cheaper. Moreover, for renin measurement they have 
the theoretical advantage over plasma renin activity 
(PRA) of the independence of renin on its substrate 
(angiotensinogen).
Several studies have evaluated chemiluminescent 
assays for measuring the plasma concentration of active 
renin (DRC) and aldosterone in hypertensive patients 
[6–11]. These studies, albeit showing that compared to 
the radioimmunometric methods the DRC assay allowed 
saving labor time and costs, overall had limitations in 
that most of them were designed to compare PRA to DRC 
[6,  8–12], rather than to test the diagnostic accuracy of 
the aldosterone­renin ratio (ARR) based on DRC (ARRCL) 
and the PRA­based ARR (ARRRIA), for identifying the sub­
types of primary aldosteronism that can be diagnosed 
conclusively. Therefore, no such studies followed the 
STARD recommendations for estimating diagnostic accu­
racy [13], which dictate that a mandatory step before any 
novel test can be introduced in clinical practice entails 
validation using a “gold standard” as reference. Of note, 
a conclusive diagnosis of APA (based on the “four corners 
criteria” [5]), and of FH­1 (based on genetic testing) was 
never used as reference in these studies. Notwithstand­
ing this, the chemiluminescent assays of renin have 
rapidly replaced the PRA at many centers, which is much 
worrying as their superiority, or even equivalence, in 
terms of diagnostic accuracy over the PRA assay was 
never proven.
This study was therefore, set up to prospectively 
 evaluate the diagnostic accuracy of a novel chemilumi­
nescent automated assay for DRC and PAC in a cohort of 
consecutive referred patients with HT in whom a conclu­
sive diagnosis of APA was achieved.
Positioning of indwelling cannula in the antecubital vein and 1 h lying supine 
Consecutive patients referred to the HT center for work-up
n=260
Establishment of final diagnosis of HT by the Adjudication Committee
Comparison of AUC  of ROC curve (accuracy)
of ARRRIA and ARRCL for identification of APA
Comparison of PRA vs. DRC, and PACCL vs. PACRIA
n=254
Exclusion due to
protocol violation,
missing values, or
duplicates
n=6
Blood sampling for renin and aldosterone
Blind assay of PRA and PAC by RIA Blind assay of DRC and PAC by CL 
Blood collection and centrifugation
at 4 °C and rapid freezing
Blood collection and centrifugation
at RT and rapid freezing
Captopril administration
(50 mg) and repeated blood
sampling after 1 h supine
Figure 1: Flow-chart of the study.
After exclusion of six patients due to various reasons 254, were analyzed. For the assays the plasma samples were assigned to different 
technicians who were blind to the clinical diagnosis and to the results of the other tests. See text for explanations. HT, hypertension; RT, 
room temperature; PRA, plasma renin activity; PAC, plasma aldosterone concentration; RIA, radioimmunoassay; CL, chemiluminescence; 
ARR, aldosterone renin ratio; APA, aldosterone producing adenoma.
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Materials and methods
Study design
The study protocol followed the requirements of the Declaration 
of Helsinki and the Statement for reporting Studies of Diagnostic 
 Accuracy (STARD) recommendations [5, 13]. The flow­chart of the 
study is shown in Figure 1: in brief, paired plasma samples from each 
patients were collected and submitted to pre­analytical handling as 
required for the DRC and the PRA assays. Two technicians, each kept 
totally blind to clinical data, the conclusive diagnosis of the type 
of HT, and to the results of the other renin and PAC measurements, 
independently performed the assays.
Based on previous experience [14] we determined beforehand 
that at least 230 patients were needed to achieve acceptable results; 
given an anticipated attrition rate a 10% we enrolled 260 consecu­
tive consenting patients referred to the Clinica dell’Ipertensione 
Arteriosa, Centro Regionale Specializzato, Regione Veneto, Center 
of Excellence of the ESH, for the evaluation of HT. Exclusion criteria 
entailed heart failure, liver cirrhosis, type 1 diabetes mellitus, and 
any other major illness that could affect life expectancy and/or the 
renin angiotensin­aldosterone system. An Adjudication Committee 
made by experienced clinicians (GPR, TMS and GM) made the final 
diagnosis of the cause of HT.
Subjects and methods
For a detailed description of the pharmacological preparation of the 
patients and the conditions for testing, please refer to the Supple­
mental Material.
Biochemical measurements
All biochemical measurements were centralized and performed in 
the ISO 9001­certified central laboratory of the Azienda Università­
Ospedale­Padova as detailed in the Supplemental Material.
DRC and PAC were measured shortly after blood sampling in 
the ad hoc collected samples using an automated system (DiaSorin, 
LIAISON® XL instrument), the LIAISON® Direct Renin kit (DiaSorin, 
Saluggia, Italy) and the LIAISON® XL Aldosterone kit. Normal ranges 
and antibody cross­reactivity for the hormonal measurements have 
already been reported [5].
ARRRIA and the ARRCL calculation and diagnostic  criteria
The ARR was first calculated using PAC (in ng/dL) as numerator, and 
either DRC (in mIU/L, ARRCL) or PRA (in ng/mL/h, ARRRIA) values as 
denominator. The ARR value was also recalculated after setting the 
lowest possible value of the denominator to 0.6 mIU/L (corresponding 
to the 25th percentile) and to 0.2 ng/mL/h for the DRC and PRA, respec­
tively, as described [14], to avoid over inflation due to low renin levels.
Primary aldosteronism (PA) was diagnosed in the presence of bio­
chemical evidence of PA, as shown by an elevated ARRRIA: for the diag­
nosis of APA lateralized aldosterone excess at adrenal vein sampling 
(AVS); identification of APA at surgery and/or pathology; demonstration 
of correction of the hyperaldosteronism and cure, or marked improve­
ment of the hypertension post­adrenalectomy, e.g. the “four corner cri­
teria”, were also required [5]. Patients with a high ARRRIA, who showed 
no lateralized aldosterone excess, were presumed to have idiopathic 
hyperaldosteronism (IHA). Renovascular hypertension was diagnosed 
based on demonstration of a hemodynamically significant renal artery 
stenosis at angioCT using the METRAS Study criteria [15], and a fall 
greater than 20  mmHg  systolic and diastolic blood pressure on the 
same or lowered antihypertensive drugs (dose and/or number) after 
renal revascularization [15]; familial hyperaldosteronism type 1 (FH­
1) was diagnosed by long PCR [16]; renin­producing tumor (RPT) was 
diagnosed based on  biochemistry, imaging and renal venin sampling.
Further tests
The patients with an ARR exceeding the cutoff values at baseline 
and post­captopril (27 and 13 ng/dL/ng/mL/h, respectively) [5] were 
 submitted to AVS to identify a lateralized aldosterone excess produc­
tion, and to an imaging test for identification of adrenocortical  nodule 
[5, 17, 18]. Only bilaterally selective AVS were used to demonstrate lat­
eralization of hyperaldosteronism [18]. As the bilateral simultaneous 
blood sampling technique was used, we did not perform AVS with 
cosyntropin because we previously showed that despite improving 
the assessment of selectivity of catheterization this stimulation does 
not enhance the diagnostic accuracy [19].
Statistical analysis
DRC, PRA, PAC, and ARR values were skewed and therefore, were 
 analyzed after a normal distribution was achieved by log transforma­
tion. One­way ANOVA with Bonferroni’s post­hoc test was used to com­
pare quantitative variables across groups. Distribution of categorical 
variables was investigated by χ2 analysis. Bland­Altman plots and Dem­
ing regression analysis were used to assess the within­patient relation­
ship between DRC and PRA, and between PACRIA and PACCL values [20]. 
Bland­Altman plots were used to detect systematic error, proportional 
error, or a magnitude­dependent bias. For the Deming regression, the 
concordance correlation coefficient, which evaluates the degree to which 
pairs of observations fall on the 45° line through the origin, was calcu­
lated. This coefficient is a measure of accuracy and was estimated by the 
following formula: ρc = ρ Cb, with ρ indicating the Pearson correlation 
coefficient and Cb indicating a bias correction factor that measures how 
far the best­fit line deviates from the 45° line through the origin. Given 
the different ranges of values furnished by these assays the Z score were 
calculated from the raw values and used for the latter analyses.
The receiver operator characteristics (ROC) curves were 
employed to assess the accuracy of the ARRCL and the ARRRIA for 
identifying APA [21]. The area under the ROC, used as an estimate 
of diagnostic accuracy, was compared between the ARRCL and the 
ARRRIA with the method of Hanley [22]. The Youden index (J), a main 
summary statistic of the ROC curve defined as J = max (c)  [sensitivity 
(c)+specificity (c)−1], was employed to determine the optimal  cutoff 
(c*). This was defined as the value that optimizes the ARR’s dis­
criminating ability in that it corresponds to the highest average of 
sensitivity and specificity [23]. The significance was set at p < 0.05. 
SPSS™ for Mac (vers. 22.0) was used for all but the ROC curve analy­
ses, which were performed with the MedCalcTM software (vers. 15.6 
MedCalc Software, Mariakerke, Belgium).
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Results
Baseline characteristics
Between April 2014 and April 2015 260 consecutive newly 
referred patients with HT were recruited. Of them six 
were excluded due to protocol violations, missing data or 
Table 2: Anthropometric and clinical features of the patients in the main diagnosis groups.
Variable   PA (n = 69)   p-Value    RVH (n = 6)   p-Value    PH (n = 171)   p-Value
PA vs. RVH RVH vs. PH PH vs. PA
Age, years   48.9±11.4  ns   39.4±15.1  ns   45.2±14.1  ns
Gender (m/f, %)   62/38  ns   50/50  ns   55/45  ns
Systolic BP, mmHg   150±19  ns   147±18  ns   143±15  ns
Diastolic BP, mmHg   93±15  ns   93±14  ns   90±12  ns
Serum K+, mmol/L   3.6±0.5  ns   3.9±0.2  ns   4.0±0.4   < 0.0001
PRAb, ng/mL/h   0.34 (0.26–0.41)   < 0.0001   1.87 (0.56–3.19)  0.001   0.80 (0.68–0.91)   < 0.0001
PRAc, ng/mL/h   0.45 (0.32–0.59)   < 0.0001   6.52 (0.39–15.80)   < 0.0001   1.38 (1.13–1.63)  0.003
DRCb, mIU/L   5.34 (4.07–6.60)   < 0.0001   32.87 (16.43–49.30)  0.03   17.54 (15.04–20.03)   < 0.0001
DRCc, mIU/L   8.30 (5.75–10.85)   < 0.0001   88.74 (9.98–167.50)   < 0.0001   26.69 (22.38–31.00)   < 0.0001
PACbRIA, ng/dL   19.6 (16.1–23.1)  ns   21.1 (9.1–33.1)  0.01   10.1 (9.4–10.9)   < 0.0001
PACcRIA, ng/dL   15.8 (12.9–18.7)  ns   12.9 (5.1–19.9)  ns   6.9 (6.5–7.3)   < 0.0001
PACbCL, ng/dL   18.2 (14.7–21.7)  ns   22.7 (11.6–33.9)  0.002   9.6 (9.0–10.3)   < 0.0001
PACcCL, ng/dL   16.6 (12.7–20.4)  ns   16.4 (9.7–23.1)  ns   7.6 (7.2–8.0)   < 0.0001
ARRbRIA (ng/dL)/(ng/mL/h)   99.6 (76.3–123.0)   < 0.0001   12.8 (6.9–18.8)  ns   22.2 (19.0–25.6)   < 0.0001
ARRcRIA (ng/dL)/(ng/mL/h)   76.3 (53.5–99.0)  0.004   6.3 (1.3–11.2)  ns   14.3 (11.1–17.4)   < 0.0001
ARRbCL (ng/dL)/(mIU/L)   7.5 (5.3–9.7)  0.005   0.9 (0.4–1.3)  ns   1.0 (0.8–1.1)   < 0.0001
ARRcCL (ng/dL)/(mIU/L)   5.2 (3.5–6.9)  0.009   0.4 (0.1–0.6)  ns   0.7 (0.5–0.8)   < 0.0001
Median and 95% CI range, as appropriate. PA, primary aldosteronism; RVH, renovascular hypertension; PH, primary (essential) hyperten-
sion; BP, blood pressure; PRAb, plasma renin activity (PRA) at baseline; PRAc, PRA after captopril; DRCb, direct renin concentration (DRC) 
at baseline; DRCc, DRCRIA after captopril; PACbRIA, plasma aldosterone concentration (PAC) measured with radioimmunoassay (RIA)-based 
technique at baseline; PACcRIA, PAC measured with RIA after captopril; PACbCL, PAC measured with chemiluminescent assay at baseline; PACcCL, 
PAC measured with chemiluminescent assay after captopril; ARRbRIA, PAC-to-PRA ratio calculated using PAC measured with RIA as numerator 
and PRA value as denominator, at baseline; ARRcRIA, PAC-to-PRA ratio calculated using PAC measured with RIA as numerator and PRA value as 
denominator, after captopril; ARRbCL, PAC-to-DRC ratio calculated using PAC measured with chemiluminescent assay as numerator and DRC 
as denominator, at baseline; ARRcCL, PAC-to-DRC ratio calculated using PAC measured with chemiluminescent assay as numerator and DRC 
as denominator, after captopril.
Table 1: Baseline characteristics of the entire cohort of consecutive 
hypertensive patients.
Variable   All patients (n = 254)
Age, years   46.1±13.5
Gender (m/f, %)   57/43
BMI, kg/m2   28.4±9.7
Systolic BP, mmHg   146±17
Diastolic BP, mmHg   91±13
Serum Na+, mmol/L   141.2±2.0
Serum K+, mmol/L   3.9±0.5
Urinary Na+ excretion, mmol/24 h  171±77
Urinary K+ excrextion, mmol/24 h   65±23
Serum creatinine, μmol/L   69±22
eGFR, mL/min/1.73 m2   110±64
duplicated (n =1). Of the remaining 254 patients, 67.3% had 
primary hypertension (PH) and 32.7% secondary HT. In the 
latter group, 17.3% (of the total) had an APA, 11.4% IHA, 
2.4% RVH due to atherosclerotic renal artery stenosis, 0.8% 
(two patients) FH­1, 0.4% (one patient) apparent mineralo­
corticoid excess due to licorice abuse and 0.4% (one patient) 
renin­producing tumor; 3.9% (ten patients) were adrenal­
ectomized APA patients studied at follow­up after surgery. 
The demographic and clinical data of the entire cohort of 
consecutive hypertensive patients (Table  1) showed that 
the patients were middle aged, overweight, with normal 
sodium intake and renal function. Table 2 shows the clini­
cal and the raw biochemical data of the patients in the 
three main groups of diagnosis; the adrenalectomized PA 
patients were not included as PA in the overall analysis.
The PA patients showed the lowest values of serum K+, 
PRA and DRC; both the PA and the RVH showed high PAC; 
however, only the former exhibited overtly elevated values 
of the ARR, regardless of the assays used for its determina­
tion. When the PA, which comprised the largest group with 
secondary HT, was examined, the APA patients showed 
slightly lower serum K+, and higher PAC and ARR values, 
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albeit only for the ARRCL. The blood pressure values were 
significantly lower in the adrenalectomized APA than in the 
APA studied before adrenalectomy; moreover, their PRA 
and DRC values increased, and the PAC values fell, as com­
pared to the pre­adrenalectomy group (Table S1). The base­
line and post­captopril values of the ARRRIA and  ARRCL in 
the patients divided by final diagnosis (Figure 2)  evidenced 
a remarkable similarity between values determined with 
either method across all groups. The corresponding values 
of PRA, DRC, and PAC also showed prominent similarity 
(Figures S1 and S2), as assessed by the concordance cor­
relation coefficient, which was 0.92 and 0.93 for renin and 
PAC, respectively (Figure S3).
Relationship between the DRC and the PRA 
and PACRIA and PACCL
The DRC and PRA values showed a significant within–
patient correlation in the whole cohort, both at baseline 
(r = 0.91 (0.89–0.93), p < 0.0001 and post­captopril (r = 0.88 
(0.85–0.91), p < 0.0001), thus indicating a high between­
method concordance in the all range of plasma renin levels 
(Figure S3). The PACRIA and PACCL values also showed a sig­
nificant within–patient correlation in the whole cohort, 
both at baseline (r = 0.93 (0.91–0.94), p < 0.0001) and post­
captopril (r = 0.88 (0.84–0.90), p < 0.0001). Therefore, there 
was a high between­method concordance in a wide range 
of PAC levels spanning from those found in patients with 
low PAC (AME and FH­1 under dexamethasone treatment) 
and high PAC values (PA and RVH patients).
Diagnostic accuracy of the ARRRIA and the 
ARRCL
Figure 3 shows the Bland­Altman plot of the ARRRIA and 
the ARRCL. The Z scores were used for this plot to avoid cre­
ating an artificial proportional error (due to the different 
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Figure 2: Box and whisker plots of the aldosterone-renin ration (ARR) values calculated using PAC and DRC measured with the automated 
chemiluminescent method (ARRCL lower panels) or with radioimmunoassay of PAC and PRA (ARRRIA upper panels) in the 254 patients divided 
according to the final diagnosis.
The left panels show the baseline values while the right panels depict the values obtained after captopril challenge. Please note the 
remarkably similar results obtained with the different methods under both conditions, the ARR values higher in the APA group than in the 
PH and RVH groups, and the markedly lower values in the adrenalectomized APA patients and in the patient with a renin-producing tumor.
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units of measure of the assays). Although eyeball exami­
nation suggested a ‘funnel effect’, e.g. a magnitude­
related (proportional) difference between the methods, no 
evidence for systematic biases was detected: only 10 of the 
254 values fell out of the 95% confidence interval.
The ROC curves AUC for ARRCL and ARRRIA for the 
unambiguously diagnosed APA, used as reference, dif­
fered significantly from that under the identity line, for 
both ARRs indicating that they provided a diagnostic gain 
in over tossing a coin (Figure 4). However, the AUC for 
Figure 3: Bland-Altman plot showing the comparison of the ARRRIA 
and the ARRCL values (plotted as Z scores of the raw values).
See text for explanation.
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Figure 4: The comparison of the ROC curves for the ARRCL and the 
ARRRIA measured under baseline conditions for the identification of 
APA, as conclusively established by using the ‘four corners’ criteria, 
shows a higher area under the curve (AUC) for the ARRCL than for the 
ARRRIA, indicating a better performance of the former over the latter.
ARRCL was higher than that for ARRRIA (p = 0.02). Results 
were similar when the analysis was repeated after con­
straining the lowest value of DRC to 6 mIU/L, and the PRA 
to 0.2 ng/mL/h, the values used in clinical practice when 
calculating the ARR to avoid over­inflating its values due 
to exceedingly low renin values [5, 24].
Optimal cutoff of the ARRCL for identification 
of APA
The Youden index, used to identify the optimal cutoff 
for the raw and corrected ARRCL, was 2.06 for the raw 
ARRCL expressed as PAC in ng/dL and DRC as mUI/L, 
which corresponded to a sensitivity of 92% and a speci­
ficity of 91.6% (Table 3). For the ARRRIA the optimal cutoff 
value (in ng/dL/ng/mL/h) was 38.7, corresponding to a 
sensitivity of 80% and a specificity of 92%. Results were 
similar when the analysis was repeated after constrain­
ing the lowest DRC value to 6 mIU/L, and the PRA to 
0.2 ng/mL/h.
Discussion
The direct immunochemical measurement of active renin 
is rapidly replacing PRA for several potential advantages 
including independence on renin substrate availability, 
more consistent results, handling of plasma at room tem­
perature, and the possibility of performing the assay with 
automation, thus saving time, costs and human resources. 
Accordingly, the replacement of the PRA with the chemi­
luminescent renin assay has rapidly occurred at many 
centers in spite of lack of any proof for superiority of the 
former over the latter in terms of diagnostic accuracy. The 
available studies mostly investigated the correlation of 
DRC with DRA [6–11]; only one retrospective study vali­
dated a chemiluminescent assay in PA patients, but did 
not compare the ARRCL, with the ARRRIA [12].
We planned this study in 2013 to prospectively 
compare head­to­head the ARR obtained from an auto­
mated simultaneous chemiluminescent measurement of 
PAC and DRC (ARRCL) with the ARR based on established 
and clinically validated PRA and PAC radioimmunoassay 
(ARRRIA) in a sizable cohort of patients. According to the 
protocol, we selected no specific forms of HT as we wished 
to test the performance of these assays in a real life situ­
ation entailing a cohort of consecutively referred hyper­
tensive patients. Hence, we recruited mostly patients 
with essential HT, but also, consistently with the referral 
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nature of our center, a notable proportion with secondary 
forms of HT, among which primary aldosteronism largely 
prevailed, but other forms, including renovascular HT, 
FH­1, renin­producing tumor, and apparent mineralocor­
ticoid excess were also represented. Moreover, as a result 
of our policy of systematically assessing the patients 
post­adrenalectomy to prove correction of the PA, there 
were also APA patients who were studied at follow­up 
post­adrenalectomy. Altogether these features testified 
the ‘real life’ setting of this study and allowed to compare 
the two assays over a wide range of renin and PAC values.
Of note, the secondary forms of HT were diagnosed 
unambiguously by state­of­the art criteria: for APA and 
FH­1, the subtypes of PA that can be unequivocally diag­
nosed, by the “four corners criteria” and long PCR, respec­
tively [5, 17]. Since, as expected FH­1 was found only in two 
Table 3: Area under the ROC Curve (AUC) for the aldosterone-to-renin ratio (ARR) measured with the chemiluminescence-based technique 
and the optimal criterion value.
ROC curve
 Disease prevalence, %   12.3
Area under the ROC curve (AUC)
 Area under the ROC curve (AUC)   0.971
 Standard errora   0.014
 95% Confidence interval   0.937–0.989
 Z statistic   32.71
 Significance level p (Area = 0.5)    < 0.0001
Youden index
 Youden index J   0.8362
 Associated criterion    > 2.057
 Sensitivity   92.00
 Specificity   91.62
Optimal criterionb
 Optimal criteriona    > 5.029
 Sensitivity   80.00
 Specificity   98.88
aTaking into account disease prevalence (12.3%) and estimated costs: cost false positive: 1; cost false negative: 1; cost true  positive: 0; cost 
true negative: 0. bThe optimal criterion value takes into account not only sensitivity and specificity, but also disease prevalence and costs 
of various decisions.
Criterion values and coordinates of the ROC curve
  Criterion  Sensitivity  95% CI  Specificity  95% CI  +LR  –LR  +PV  –PV  Cost
   ≥ 0.063  100.0  86.3–100.0  0.0  0.0–2.0  1.00    12.3    0.88
   > 0.905  100.0  86.3–100.0  69.8  62.5–76.5  3.31  0.00  31.6  100.0  0.27
   > 0.915  96.0  79.6–99.9  69.8  62.5–76.5  3.18  0.057  30.8  99.2  0.27
   > 1.461  96.0  79.6–99.9  83.2  76.9–88.4  5.73  0.048  44.4  99.3  0.15
   > 1.467  92.0  74.0–99.0  83.2  76.9–88.4  5.49  0.096  43.4  98.7  0.16
→   > 2.057  92.0  74.0–99.0  91.6  86.6–95.2  10.98  0.087  60.5  98.8  0.08
   > 2.094  88.0  68.8–97.5  91.6  86.6–95.2  10.50  0.13  59.5  98.2  0.09
   > 2.827  88.0  68.8–97.5  94.4  90.0–97.3  15.75  0.13  68.7  98.3  0.06
   > 2.829  84.0  63.9–95.5  94.4  90.0–97.3  15.04  0.17  67.7  97.7  0.07
   > 3.285  84.0  63.9–95.5  96.1  92.1–98.4  21.48  0.17  75.0  97.7  0.05
   > 3.328  80.0  59.3–93.2  96.1  92.1–98.4  20.46  0.21  74.1  97.2  0.06
   > 5.029  80.0  59.3–93.2  98.9  96.0–99.9  71.60  0.20  90.9  97.3  0.03
   > 7.079  60.0  38.7–78.9  98.9  96.0–99.9  53.70  0.40  88.2  94.7  0.06
   > 7.125  60.0  38.7–78.9  99.4  96.9–100.0  107.40  0.40  93.7  94.7  0.05
   > 8.572  40.0  21.1–61.3  99.5  96.9–100.0  71.60  0.60  90.9  92.2  0.08
   > 8.888  40.0  21.1–61.3  100.0  98.0–100.0    0.60  100.0  92.3  0.07
   > 44.88  0.0  0.0–13.7  100.0  98.0–100.0    1.00    87.7  0.12
The arrow and bold indicate the cutoff value that meets the optimal sensitivity and specificity. +PV, positive predictive value; –PV, negative 
predictive value; +LR, positive likelihood ratio; –LR, negative likelihood ratio [25].
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cases, we used APA as reference index to determine the 
accuracy of either ARR following the STARD recommen­
dations [13]. The diagnostic accuracy of the ARRCL and the 
ARRRIA for identifying APA could then be compared using 
the ROC curve analysis.
When the entire cohort was examined, both the PRA 
and DRC, and the PAC values, and consequently the 
ARRRIA and ARRCL (Figure 2) showed remarkably similar 
results and, more importantly, the expected differences 
across diagnosis groups (Table 2 and Figures S1 and S2). 
The renin values were lower in the PA group than in the 
PH and the RVH group with both assays; moreover, both 
PACRIA and PACCL values were higher in the PA and RVH 
patients than in the PH patients, as expected. Of note, the 
highest DRC value was observed in the patient with the 
renin­producing tumor, in which the PRA values were not 
so prominently elevated. This finding, along with the fact 
that another such case was identified at our center in the 
past few months after the introduction of the DRC assay, 
suggests that this assay, by circumventing the underesti­
mation of renin with the PRA assay (due to dependency 
on limiting) substrate availability), can improve the detec­
tion of rate of this rare cause of HT.
We found that the DRC and PRA values were tightly 
within­patient correlated in the whole cohort, both 
for the baseline and for the post­captopril stimulation 
(Figure  S3). This finding is at variance with what we 
found in a smaller retrospectively investigated cohort of 
the PAPY study, where only the post­captopril PRA and 
DRC values correlated strongly [14]. We speculated at that 
time that the stronger correlation post­captopril could 
be because of the higher precision of both renin assays 
when renin values are raised. Instead the present find­
ings showed that the PRA and DRC correlated well also 
in the low renin range, e.g. in PA patients under unstimu­
lated conditions. Likely this different better outcome orig­
inated from several factors: the very rigorous control of 
the pre­analytical phase that avoided inadvertent altera­
tion of renin measurement due to cryoactivation [6, 26], 
use of an automated method in a centralized laboratory, 
along with a storage time duration much shorter than in 
the PAPY Study [14].
The notable precision of the automated DRC assay to 
measure the low renin levels of PA patients agrees with the 
findings of a highly significant correlation between PRA 
and DRC in plasma samples with low renin concentration 
(mean value of 1.63 mIU/L, range 0.8–11.7) in PA patients, 
as well as with the manufacturer’s claim that the LIAISON 
Direct Renin kit has a functional sensitivity of 2 (1.60–1.96 
IFU DS) mIU/L. This finding is obviously relevant from the 
practical standpoint and supports the contention that the 
ARRCL could be at least as accurate as ARRRIA in identifying 
PA patients [18].
To further investigate the accuracy of the two ARR we 
used the AUC under the ROC curves, which estimates the 
overall diagnostic accuracy because it provides an index 
of the average sensitivity for all values of specificity, and 
vice versa. For the ARRCL and the ARRRIA the AUC was 
higher than 0.50, indicating that both tests are useful for 
the screening of APA over “tossing a coin”. More impor­
tantly, the accuracy of the ARRCL was higher than that 
of the ARRRIA: a formal comparison of the ARRCL and the 
AUC ARRRIA showed that the AUC for the former test (0.974 
(95% CI 0.940–0.991) was higher than that of the latter 
(0.894 (95% CI 0.841–0.933, p = 0.02) (Figure 4). Identi­
cal conclusions were reached when the ROC analysis 
was repeated after constraining the lowest limit of DRC­ 
and PRA measured renin values at the aforementioned 
minimum values.
The optimal cutoff for the raw ARRCL (expressed as 
PAC in ng/dL and DRC as mIU/L, Table 2), was 2.06; it 
corresponded to a sensitivity of 92% and a specificity of 
92% (Table 3); for the ARRRIA the optimal cutoff value was 
38.7 (expressed as PAC in ng/dL and PRA as ng/mL/h) 
corresponding to a sensitivity of 80% and a specificity of 
92%. This ARRCL cutoff is higher than the 1.2 reported for 
another chemiluminescent assay in a retrospective study, 
in which, however, the diagnosis of APA was not unam­
biguously confirmed by the four corner criteria (12). With 
that cutoff, however, in spite of slightly higher sensitivity 
(98.9% vs. 92%) the specificity was much lower compared 
to that found in the present study (79% vs. 92%). More­
over, to enable readers to select the ARRCL cutoff values 
that best meet their desired combination of sensitivity and 
specificity we have provided a table with the sensitivity, 
specificity, positive (+PV) and negative predictive value 
(–PV), positive likelihood ratio (+LR), negative likelihood 
ratio (–LR), and also the optimal criterion value, which 
takes into account not only sensitivity and specificity, but 
also disease prevalence, and costs of various decisions 
(Table 3).
It might be argued that extrapolation of these find­
ings to the general population of hypertensives is not 
warranted because we examined patients referred to a 
specialized hypertension center, who show a prevalence 
of secondary forms of hypertension much higher than 
that found in the hypertensive patients commonly seen 
in general practice. However, the prevalence of second­
ary forms of HT was lower than the 50% reported in a 
recent multicenter study of patients with resistant HT [2]; 
moreover, our cohort had an overall prevalence of PA of 
27%, higher than that (11.2%) found in the all PAPY Study 
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[5]. Nonetheless, the rate of the different subtypes was 
similar, which would speak against a selection bias and 
overall support the generalizability of our findings to the 
population of referred hypertensive patients.
Strengths of this study include its prospective design, 
a careful standardization of the conditions for patient’s 
preparation, blood sampling and biochemical assay (see 
Supplemental Material), and, moreover, se of an accepted 
methodology based on the conclusive diagnosis of 
 secondary HT, namely of APA, as reference index for the 
diagnosis of PA [5, 17, 27].
These results allow, in our view, the following conclu­
sions: in patients adequately prepared from the pharma­
cological standpoint, when samples are properly collected 
and handled under carefully standardized conditions, the 
diagnostic performance of the ARR based on DRC is equiv­
alent to that based on a clinically validated PRA assay in a 
wide range of clinical conditions. Moreover, for the detec­
tion of PA, a common cause of secondary HT that is most 
challenging for the renin assays because of its low or very 
low renin values, the ARRCL obtained from PAC and DRC 
measured with an automated chemiluminescent method 
performed better than the ARRRIA. Major advantages of 
the this method for estimating active renin over the PRA 
assay include a simpler pre­analytical handling with 
blood collection and at room temperature and automa­
tion, which translated in more reproducible results and in 
less hands­on use of human resources. Finally, lack of use 
of radioactivity and radioactive waste make these assays 
environment friendly. Based on these considerations 
we have now introduced the chemiluminescence­based 
assays instead of the PRA and PAC radioimmunoassay at 
our institution. This has allowed a marked shortening of 
the time from blood sampling to results, with the benefits 
of speeding up reaching the diagnostic conclusions.
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